Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the development of cell culture technologies and techniques for therapeutic applications. Its commercial products include good tissue practice laboratory infrastructure, adipose-derived stem cells (ADSC) for regenerative medicine, and CIK and DC-CIK against cancers. The company also develops medicines for various types of cancers, cell immunotherapy, and stem cell regenerative therapy technologies. In addition, it engages in the research and development of chimeric antigen receptor T cell (CAR-T), CAR-NK and CAR-γδT, and gene-modified ADSC. Further, the company develops products for B-NHL, ovarian cancer, multiple myeloma, and thyroid cancer indications. The company was founded in 2017 and is based in Taipei, Taiwan.

Sector

Healthcare

Industry

Biotechnology

CEO

Lin, Cheng Long

Employees

Website

www.pellbmt.com

IPO Date

Headquarters

No. 87, Xinhu 2nd Rd., 4th Floor, Neihu Dist., Taipei Taiwan

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.